Short‐duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study)
- 2 February 2017
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 37 (6) , 836-842
Abstract
Background & Aims: The phase 2, FOURward study (NCT02175966) investigated short‐duration therapy (4/6 weeks) with four direct‐acting antivirals (DAAs) with distinct mechanisms of action in patients infected with hepatitis C virus (HCV) genotype‐1.Methods: Non‐cirrhotic patients were randomized 1:1 to DCV‐TRIO (fixed‐dose daclatasvir 30 mg, asunaprevir 200 mg and beclabuvir 75 mg) twice‐daily + sofosbuvir 400 mg once‐daily for 4 or 6 weeks. The primary endpoint was sustained virological response at post‐treatment Week 12 (SVR12). Patients without SVR12 were offered retreatment based on the DAA resistance profile at failure; patients with resistance to ≤1 DCV‐TRIO component received DCV‐TRIO + RBV for 12 weeks.Results: Twenty‐eight patients with HCV genotype‐1 were enrolled; 79% had genotype‐1a infection and median baseline HCV‐RNA levels were high (9 × 106 IU/mL). Most patients had undetectable HCV‐RNA at end of treatment (96% [n=27/28]); however, relapse occurred in 77% (n=10/13) and 43% (n=6/14) treated for 4 and 6 weeks, leading to SVR12 rates of 29% (n=4/14) and 57% (n=8/14) respectively. SVR12 was higher in patients with lower baseline HCV‐RNA (<2 million IU/mL, 71% [n=5/7]; ≥2 million IU/mL, 33% [n=7/21]). None of the 16 non‐SVR12 patients had NS3 or NS5B resistance‐associated substitutions (RAS) detected at failure. All 15 patients retreated with DCV‐TRIO + RBV for 12 weeks achieved SVR12. All regimens were well tolerated.Conclusions: Short‐duration treatment with four DAAs with distinct mechanisms of action was insufficient for most patients with genotype‐1 infection and high baseline viraemia. Non‐SVR12 was not associated with emergence of NS3 or NS5B RAS and retreatment with DCV‐TRIO + RBV for 12 weeks led to SVR in all patients.Keywords
Funding Information
- Bristol-Myers Squibb
- National Institutes of Health (K24DA034621)
This publication has 16 references indexed in Scilit:
- Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)Hepatology, 2016
- Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrenceHepatology, 2016
- Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 InfectionAnnals of Internal Medicine, 2015
- Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1New England Journal of Medicine, 2015
- Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 InfectionJAMA, 2015
- Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated CirrhosisJAMA, 2015
- Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort studyThe Lancet, 2015
- All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III studyHepatology, 2015
- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV InfectionNew England Journal of Medicine, 2014
- Single- and Multiple-Ascending-Dose Studies of the NS3 Protease Inhibitor Asunaprevir in Subjects with or without Chronic Hepatitis CAntimicrobial Agents and Chemotherapy, 2012